index (AI), which is the ratio of the IC 50 for the field strain/IC 50 for the susceptible reference laboratory strain (L. infantum MHOM/ MA/67/ITMAP263), was calculated, with AI ≥4 denoting drug resistance. Intraspecific genetic variability was checked using kDNA minicircles PCR-RFLP fingerprinting. A direct PCR was applied using the primers LIN-R4 (5 ′ -GGT TGG TGT AAA ATA GGG-3 ′ ) and LIN-19 (5 ′ -GAA CGC CCC TAC CCG-3 ′ ). 4 Each PCR product was digested using HaeIII and RsaI restriction enzymes, and fragments were visualized after gel electrophoresis.
Various drug susceptibility phenotypes were identified ( III susceptible (R/S; n ¼ 6); and Sb V resistant/Sb III intermediate resistant (R/I; n ¼ 3). Isolates with the R/R phenotype were not found, although this phenotype has been reported for other Leishmania species. 5, 6 We noted a clear trend for a higher proportion of Sb V -resistant isolates among HIV-positive patients (7/9 Sb V -resistant isolates versus 2/6 among HIV-negative patients), but a considerably larger sample size would be required to confirm the significance of this difference.
Our results demonstrate the occurrence of primary Sb V -resistant L. infantum isolates among the two categories of VL patients. The existence of this phenomenon among HIVpositive patients can best be explained by the anthroponotic transmission suggested to occur among them.
7 This is supported here by the observation of identical kDNA-RFLP patterns in four isolates that were collected from three different HIV-positive patients over a time period of 4 years in Mato Grosso do Sul, Brazil, two of them originating from the same patient before and after treatment (Table 1 ). This contrasts with the unique patterns observed for all of the other isolates. On the other hand, the occurrence of primary resistance in HIV-negative patients is normally not expected in the context of zoonotic L. infantum. A similar observation was already made in Leishmania braziliensis 6 and could be explained by domestication of the natural transmission cycle or anthroponization through the vicinity of HIV-positive patients. Resistant strains could also be acquired from dogs previously exposed to antimonials. In Brazil, treatment of dogs with human medications is officially prohibited, but unauthorized use is not a rare situation.
Taking all observations together, our results clearly highlight the need for epidemiological monitoring of L. infantum antimony (Sb III and Sb V ) resistance in HIV-positive and HIV-negative patients, to better understand the dynamics of the emergence and spread of this phenomenon. Similarly, particular emphasis should be put on the follow-up of treatment outcome in patients infected with the different phenotypes, as observed here. On the one hand, the therapeutic efficacy of Sb V may theoretically not be hampered, since Sb V becomes reduced to the active Sb III , 8 to which most isolates were still susceptible; on the other hand, the relation between in vitro susceptibility phenotype and treatment outcome still needs to be substantiated in many more patients and locations. Previous studies in Leishmania donovani and L. braziliensis already indicated that the relationship between treatment outcome and in vitro drug resistance is not necessarily straightforward. 3, 5, 6 In the case of L. infantum, the zoonotic reservoir in dogs should be considered as well. 
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Sir, Linezolid is an antibiotic with bacteriostatic activity against Gram-positive microorganisms licensed for complicated skin and soft tissue infections and pneumonia, but not for bacteraemia with or without endocarditis. However, the most recent guidelines from the Infectious Diseases Society of America consider linezolid an alternative treatment for catheter-related bacteraemia caused by Gram-positive organisms. 1 Twelve patients cared for at Cisanello Hospital in Pisa received linezolid for the treatment of native valve (n¼ 7), prosthetic valve (n¼ 1) or pacemaker (PM) endocarditis (n ¼4) due to Grampositive organisms: three methicillin-susceptible Staphylococcus aureus (MSSA); three methicillin-resistant S. aureus (MRSA); three methicillin-resistant Staphylococcus epidermidis (MRSE); one vancomycin-resistant Enterococcus faecium (VRE); and two polymicrobial (one Streptococcus bovis+ MRSE and one E. faecium + Enterococcus durans). Linezolid was given for failure of previous therapy (seven), renal toxicity due to vancomycin and amikacin combined therapy (one) or oral maintenance therapy (four). Two further patients, with MSSA native (one) and prosthetic (one) aortic valve endocarditis, received linezolid as continuous infusion as primary therapy.
The serum bactericidal test (SBT) of patients receiving linezolid was performed according to the usual methods. Table 1 summarizes the characteristics of patients and treatment regimens.
Linezolid was administered at a dose of 1200 mg by continuous infusion over 24 h in two patients, 600 mg twice daily by the intravenous (iv) route in eight patients and by the oral route (as consolidation therapy or because there was no venous access) in four patients.
Overall response to linezolid was 12/14 (86%), which is comparable to data reported previously. 3 Two patients died: one was a drug addict with MSSA endocarditis and cerebral embolic lesions contraindicating surgery; and the other one had MRSA PM endocarditis, but the PM was not removed because the patient's condition was too severe.
Six patients were cured with antibiotic therapy alone and six with antibiotics and surgery (three) or electrocatheter removal (three).
Response of MRSA and MSSA endocarditis was 2/3 (67%) and 4/5 (80%), respectively. All other cases were cured: one VRE; three MRSE; and two cases of polymicrobial endocarditis.
Response of native valve endocarditis was 7/8 (87.5%) and that of prosthetic valve endocarditis was 2/2 (100%). In three out of four patients with PM endocarditis (75%), the removal of the PM combined with antibiotic therapy, linezolid monotherapy in one case, was able to heal the infection. In these three patients, PM culture was still positive for the same S. epidermidis strain as isolated from the blood, probably due to the inactivity of linezolid against slime-producing bacteria. 4 Therefore, for PM endocarditis, linezolid may be an option only if the entire device is removed.
Patients were followed up for at least 6 months, and no relapses were recorded.
Two patients received linezolid as primary therapy, administered by continuous iv infusion, combined with meropenem (Patients 13 and 14 in Table 1 ). Linezolid was first started as empirical therapy by intermittent infusion and continued after the diagnosis of endocarditis was made. In Patient 13, during intermittent administration, linezolid serum concentration was 9 mg/L at peak and 1.5 mg/L at trough and the SBT titre was 1:2 for both samples; during continuous infusion the linezolid serum concentration was 4 mg/L and the SBT titre was 1:16. In Patient 14, during intermittent administration, linezolid serum concentration was 7 mg/L at peak and 2 mg/L at trough and the SBT titre was 1:2 for both samples; during continuous infusion the linezolid serum concentration was 5 mg/L and the SBT titre was 1:8.
In Patients 13 and 14, the MBC for MSSA was only 2 mg/L, within the range of susceptibility. This result may be important because linezolid is considered bacteriostatic or slowly bactericidal. 5 The SBT titre of 1:16 in Patient 13 means that serum diluted 16 times was still bactericidal; the serum concentration of linezolid was 4 mg/L and the ratio between linezolid concentration and MBC (C/MBC) was only 2 and not 16. In Patient 14, the SBT titre was 1:8 with a linezolid concentration of 5 mg/L and the C/MBC was 2.5. Therefore, SBT titre might give a more accurate measure of bactericidal activity than the C/MBC. The high SBT titre in this case might be related to continuous infusion.
Pistella et al. 6 have reported that continuous infusion of linezolid may be an option for treating cerebritis complications of S. aureus endocarditis, as serum concentrations correlated with CSF levels. In Patient 13, a case of endocarditis complicated by cerebral embolism and meningitis, the high levels of linezolid achieved may explain the positive outcome.
Linezolid may be useful in cases of right-sided endocarditis complicated by lung abscesses, where it may reach higher concentrations than glycopeptides or lipopeptides. Although the pharmacokinetics of linezolid in endocardial vegetations and around prosthetic cardiac devices are unknown, the good distribution of linezolid to many compartments might favour a good effect.
Linezolid was generally well tolerated; one patient developed reversible thrombocytopenia (40000 platelets/mL) requiring drug interruption.
In conclusion, linezolid may be used as rescue therapy in severe and difficult-to-treat patients who have endocarditis.
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C. T. and F. M. have each received a speaker honorarium from Pfizer. All other authors: none to declare. Sir, A recent study by Tungsiripat et al. 1 showed a decrease in cholesterol plasma levels in HIV-infected patients after adding tenofovir to a stable antiretroviral regimen, thus suggesting a lipid-lowering effect of this drug. We analysed the modification of lipid parameters after tenofovir discontinuation in a group of patients prospectively enrolled in a pilot trial of treatment simplification to a dual therapy with atazanavir/ritonavir plus lamivudine (Atazanavir/ritonavir and Lamivudine for treatment Simplification, AtLaS study). 2 The study was conducted in accordance with the Declaration of Helsinki and national and institutional standards, was approved by the local Ethics Committee and signed informed consent was collected from all participants.
Of the 40 patients enrolled, 39 subjects were treated with atazanavir/ritonavir plus tenofovir with lamivudine or 
